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Cryptococcosis is a life-threatening fungal infection caused by the encapsulated yeasts Cryptococcus neoformans 
and C. gattii, acquired from the environment. In Latin America, as occurring worldwide, C. neoformans causes more 
than 90% of the cases of cryptococcosis, affecting predominantly patients with HIV, while C. gattii generally af-
fects otherwise healthy individuals. In this region, cryptococcal meningitis is the most common presentation, with 
amphotericin B and fluconazole being the antifungal drugs of choice. Avian droppings are the predominant environ-
mental reservoir of C. neoformans, while C. gattii is associated with several arboreal species. Importantly, C. gattii 
has a high prevalence in Latin America and has been proposed to be the likely origin of some C. gattii populations in 
North America. Thus, in the recent years, significant progress has been made with the study of the basic biology and 
laboratory identification of cryptococcal strains, in understanding their ecology, population genetics, host-pathogen 
interactions, and the clinical epidemiology of this important mycosis in Latin America.
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In Latin America, the study of cryptococcosis and its 
etiological agents has become increasingly important, as 
this mycosis has significant morbidity and mortality, with 
more than 5,000 individuals affected with cryptococcal 
meningitis each year, and 2,400 attributable annual deaths 
in Latin America alone. The main goal of this review is 
to present recent and relevant data regarding the studies 
done in Latin American countries on cryptococcosis and 
the etiological agents Cryptococcus neoformans, and C. 
gattii. Topics related to epidemiology, clinical data and 
treatment, molecular studies on clinical and environmen-
tal isolates, host-pathogen interactions, laboratory data on 
antifungal susceptibility, preliminary data detecting anti-
genemia in patients, and studies to search for the environ-
mental niche of the fungus are presented here.
Epidemiology - C. neoformans is the most impor-
tant cause of fungal meningitis in the world, and in sub-
Saharan Africa, meningeal cryptococcosis is the most 
common type of meningitis in adults infected with HIV 
(Rajasingham et al. 2017). From a total of 223,100 cases 
of meningeal cryptococcosis that were estimated to have 
occurred globally in people living with HIV in 2014, the 
third largest number of cases in the world were from Latin 
America, with an estimated incidence of 5,300 cases per 
year. From those, Brazil and Colombia were the countries 
with the highest incidence, between 1,001 to 2,500 cases, 
followed by Argentina and Mexico with an incidence of 
501 to 1,000 cases (Rajasingham et al. 2017). In particu-
lar, an average annual incidence of 4.5 cases of meningeal 
cryptococcosis per 106 inhabitants was reported in the 
general population of the state of Rio de Janeiro, Brazil 
(Leimann and Koifman 2008). In Colombia, the average 
annual incidence of cryptococcosis in the general popula-
tion has been estimated to be 2.4 cases per 106 inhabitants, 
while in the HIV-infected population this value has been 
estimated to be 3,000-3,300 cases per 106 people (Lizara-
zo et al. 2007, Escandón et al. 2012). In addition, Lizarazo 
et al. (2014a) reported an average annual incidence of 
0.0017 cases per 106 in Colombian children.
There is little data regarding the prevalence of cryp-
tococcosis in Latin America. In Mexico, a study of the 
etiological agents of meningoencephalitis found that 
the most common mycosis was cryptococcosis, with a 
prevalence of 10% (Barriga et al. 2005). In Venezuela, 
a study of systemic mycoses performed at a national 
reference centre found that cryptococcosis ranked third 
with a prevalence of 19%, following histoplasmosis and 
paracoccidioidomycosis; however, in the population with 
HIV, C. neoformans was isolated in 27% of the cases, fol-
lowing the etiological agent of histoplasmosis (Reviákina 
et al. 2007). A national survey conducted in Argentina 
identified cryptococcosis as the second most frequent 
deep fungal infection with a prevalence of 20%, follow-
ing that of yeast fungemia (Davel and Canteros 2007). In 
Mexico, C. neoformans had a prevalence of 21% caus-
ing fungemia in patients with different types of immu-
nosuppression, only following Histoplasma capsulatum 
(Gaona-Flores et al. 2016). In the same country, cryp-
tococcosis was the third most common invasive fungal 
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infection (13%) found in a highly specialised hospital, 
following candidiasis and mucormycosis (Méndez-Tovar 
et al. 2016). In Colombia, Castro-Jiménez et al. (2011) re-
ported cryptococcosis as the most common opportunistic 
mycosis in patients with HIV/AIDS, with a prevalence of 
76%. In the same population in Guatemala, it was esti-
mated that meningeal cryptococcosis is the fourth most 
common opportunistic fungal infection following candi-
diasis (esophageal), Pneumocystis jirovecii pneumonia, 
and disseminated histoplasmosis (Medina et al. 2017).
In Colombia, among opportunistic infections of the 
central nervous system (CNS) in patients with HIV, 
cryptococcosis is the second most common, after toxo-
plasmosis, which has been demonstrated in clinical stud-
ies (Lizarazo et al. 2006, Ávila and González 2007), and 
autopsies (Mantilla and Cárdenas 2009). The same find-
ings have been described in Cuba (Lamotte 2014).
Most cases of cryptococcosis are reported in young 
HIV positive male patients. Among the HIV negative 
patients, males are also the predominant sex, although in 
a smaller proportion, and patients also tend, on average, 
to be slightly older (Dromer et al. 1996). This epidemio-
logical distribution has also been found in Latin Ameri-
ca (Table I). Globally, as in many developing countries, 
many cases of cryptococcosis in Latin America may not 
be reported or be confirmed by diagnosis, which in part 
is reflected by the number of people living with AIDS 
not in care, undiagnosed, and lost to follow-up, or liv-
ing in resource-limited areas, which does not allow for a 
prompt and correct diagnosis (Rajasingham et al. 2017).
Clinical aspects - Cryptococcosis mainly affects the 
CNS, causing meningitis. In a lesser proportion it affects 
the lungs, and organs such as skin, eyes, prostate, and 
bone, among others (Maziarz and Perfect 2016). Classi-
cally, patients with meningeal cryptococcosis present a 
clinical picture consisting of headache and fever, lasting 
approximately two weeks. Many of these patients also 
present with nausea, vomiting, cranial nerve involve-
ment, and decreased visual acuity due to intracranial 
hypertension. If the disease progresses without treat-
ment, mental changes, seizures, and a decreased state 
of consciousness leading to coma are observed (Limper 
et al. 2017, Williamson et al. 2017). In Latin America, 
meningeal cryptococcosis is also the main form of clini-
cal presentation, with headache as the cardinal symp-
tom (Table I). Intracranial hypertension, one of the most 
feared complications, has been reported in several Latin 
American studies, in more than 50% of the cases (Table 
I), which suggests a high percentage of patients with ad-
vanced forms of the disease. In autopsy studies conduct-
ed in Latin America, patients with neurocryptococcosis, 
most of whom were infected with HIV, predominantly 
had disseminated forms of the disease, with multiple or-
gan involvement. Pure meningoencephalitic forms are 
less frequent, and the presence of cryptococcomas very 
rare (Reséndiz et al. 2008, Klock et al. 2009, Mantilla 
and Cárdenas 2009, Torres et al. 2016).
Treatment - For meningeal cryptococcosis, the treat-
ment of choice recommended by the guidelines of the In-
fectious Diseases Society of America (IDSA), consists of 
a combination of amphotericin B deoxycholate (AmBd) 
0.7 mg/kg/day, and 5-fluorocytosine (5FC) 100 mg/kg/
day for two weeks as induction phase, followed by flu-
conazole (FCZ) 400 mg daily for eight weeks as consoli-
dation phase, and FCZ 200 mg daily as the maintenance 
phase. In the induction phase it is recommended to use, as 
an alternative, the use of liposomal AmB (LAmB) associ-
ated (or in combination) with 5FC (Perfect et al. 2010). In 
Latin America, due to the unavailability of 5FC and the 
high cost of LAmB preparations, an alternative regimen 
recommended by the IDSA for countries with limited re-
sources, with a good level of evidence (AI), consists of 
AmBd 0.7 mg/kg/day, plus FCZ 800 mg/day for the in-
duction phase of two weeks; followed by FCZ 800 mg per 
day for eight weeks for the consolidation phase (Table II). 
An alternative scheme for the induction phase is the use of 
AmBd alone, at a dose greater than 1 mg/kg/day (Perfect 
et al. 2010). Similar considerations have been made in the 
Brazilian (Moretti et al. 2008), and Colombian (Castañeda 
and Lizarazo 2012) management guidelines.
The lethality of meningeal cryptococcosis in Latin 
America has been reported to range from 13% to 73%, 
with many cases ranging between 30% and 60% (Table 
I), which are very high figures compared to that of the 
industrialised countries (van der Horst et al. 1997), but 
similar to those recorded in sub-Saharan Africa (Jarvis 
and Harrison 2016). In Brazil, among the systemic myco-
ses, cryptococcosis causes the highest number of deaths 
in patients with HIV (Prado et al. 2009). In this country, 
the mortality rate of cryptococcal infections was 0.47 per 
million inhabitants, and was the thirteenth cause of death 
(Soares 2015). In Colombia, however, the survival rate 
of patients with meningogenic cryptococcosis has been 
reported to be 82% for HIV negative patients, and only 
46% for HIV positive patients, with a survival time of 
only four months after diagnosis (Lizarazo et al. 2012).
Molecular studies on C. neoformans and C. gattii - 
Several broadly used molecular techniques have been 
used to determine the genotype of individual isolates, and 
compare groups of isolates among C. neoformans and C. 
gattii species, to carry out molecular epidemiology and 
population genetics studies. Among these techniques, 
polymerase chain reaction (PCR) fingerprinting (Meyer 
and Mitchell 1995), amplified fragment length polymor-
phisms (AFLP) (Boekhout et al. 2001, Hagen et al. 2010), 
microsatellite typing (Illnait-Zaragozi et al. 2010a), re-
striction fragment length polymorphisms (RFLP) (Meyer 
et al. 2003), multilocus sequence typing (MLST) (Meyer 
et al. 2009), and more recently, whole genome sequenc-
ing (WGS) (Loftus et al. 2005, D’Souza et al. 2011), have 
allowed for the identification of eight major molecular 
types among the cryptococcal species in the world: VNI 
(AFLP1) and VNII (AFLP1A/B) for C. neoformans var. 
grubii serotype A isolates, VNIV (AFLP2) for C. neo-
formans var. neoformans serotype D isolates, VNIII 
(AFLP3) for hybrids between the serotypes A and D, and 
VGI (AFLP4), VGII (AFLP6), VGIII (AFLP5) and VGIV 
(AFLP7) for C. gattii serotype B, and C isolates.
Although in most of the studies on Cryptococcus and 
cryptococcosis reported from Latin America, the isolates 
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have been identified only at species level, variety, or sero-
type; it is now possible to determine the major molecular 
type of the cryptococcal isolates recovered not only from 
clinical, but also from environmental sources, and much 
less frequently from veterinary samples, by using one or 
more of the above mentioned molecular techniques.
Using these techniques, the major molecular type of 
3,486 isolates in Latin America is presently known, with 
most of the isolates reported from Brazil (45.87%), fol-
lowed by Colombia (24.99%), Mexico (9.21%), Argen-
tina (8.09%), Cuba (6.05%), Venezuela (2.90%), Peru 
(1.06%), Ecuador (0.77%), Chile (0.55%), Guatemala 
(0.43%), as well as Honduras, Paraguay, and Uruguay 
with one isolate each (Table III). From Bolivia, Costa 
Rica, Dominican Republic, El Salvador, Haiti, Nicara-
gua, and Panama, there are not data reported about the 
molecular type of cryptococcal strains.
From these 3,486 isolates, 67.7%, and 32.2% were 
recovered from clinical, and environmental sources, re-
spectively. In concordance with global data, the molecu-
lar type VNI (AFLP1), corresponding to C. neoformans 
var. grubii, serotype A is the predominant molecular 
type (72.8%) causing cryptococcosis in Latin America, 
followed by C. gattii molecular type VGII (AFLP6) 
(14.4%) (Fig. 1). Interestingly, in the environment these 
two molecular types also predominate with slightly dif-
ferent proportions (57.0% for C. neoformans VNI, and 
28.7% for C. gattii VGII) (Fig. 1), although this distribu-
tion may be biased by the high prevalence of C. gattii 
VGII in Brazil and Colombia, which are the countries 
with the largest number of studied isolates (Fig. 1, Table 
III). Of all these studies, only six C. gattii isolates (0.2%) 
have been reported from veterinary cases: one molecu-
lar type VGI from Cuba (Illnait-Zaragozi et al. 2011b) 
and five molecular type VGII from Brazil (Cardoso et 
al. 2013, Headley et al. 2015, da Silva et al. 2017) (Fig. 
1). Interestingly, in Brazil an outbreak of infection oc-
curred in a breeding aviary in São Paulo, where seven 
parrot-like birds died of disseminated cryptococcosis. 
Although the molecular type of the causative agent was 
not identified, all cases were caused by C. gattii sero-
type B, resistant to FCZ, as determined by biochemical, 
physiological, and serological testing (Raso et al. 2004). 
To date, veterinary cases of C. neoformans have not yet 
been reported in Latin American countries.
Clinical cases of cryptococcosis from which the ma-
jor molecular type of the isolates has been identified, date 
back to 1961 (Meyer et al. 2003), with most of the studies 
being retrospective. While Argentina, Brazil, Colombia, 
and Cuba have described isolates from the 1980s (Igreja 
et al. 2004, Escandón et al. 2006, Illnait-Zaragozi et al. 
2010a, Arechavala et al. 2017), most of the isolates recov-
ered in Latin America are from the mid-1990s, to date. 
Case reports, in which C. gattii has been isolated as etio-
logical agent, have been documented much more recent-
ly (Illnait-Zaragozi et al. 2013, Nascimento et al. 2014, 
Cicora et al. 2015, Solar et al. 2015, Noguera et al. 2017), 
with the earliest occurring in 2005 in Brazil (Pinto Jr et 
al. 2010). The major molecular type of the environmen-
tal isolates was first reported about two decades ago in 
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reports on the molecular types of C. neoformans and C. 
gattii from the environment are from after the year 2000.
The combined analysis of the molecular data also 
showed that in Colombia, the prevalence of the C. gattii 
VGIII is very similar to that of C. gattii VGII and that 
in Mexico, the molecular type VGIII is the most com-
mon among C. gattii isolates and the second most com-
mon after C. neoformans VNI. In Argentina however, the 
most common molecular type among C. gattii isolates is 
VGI (Fig. 2). Mexico is the only country where all major 
molecular types have been reported, while in Brazil and 
Argentina only C. gattii VGIV seems to be absent and in 
Colombia only C. neoformans VNIII has not been recog-
nised. However, apart from VNIII, the hybrid most com-
monly found in C. neoformans, inter- and intra-specific 
hybrids have been reportedly for Latin America. One 
isolate described as the VNII/VNIV hybrid was reported 
from Argentina, another isolate with the same genotype 
TABLE III
Distribution of Cryptococcus neoformans and C. gattii isolates recovered in Latin America and identified at molecular type level
Country* n Source
C. neoformans C. gattii
TotalVNI VNII VNIII VNIV VGI VGII VGIII VGIV
Brazil Clinical 695 38 - - 19 269 18 - 1039
1599 Environmental 301 8 1 23 7 215 - - 555
Veterinary - - - - - 5 - - 5
Colombia 871 Clinical 317 17 - 6 10 54 39 2 445
Environmental 229 1 - - 3 106 76 11 426
Mexico 321 Clinical 209 21 12 7 11 5 26 7 298
Environmental 18 - - - - - 5 - 23
Argentina 282 Clinical 209 13 9 2 3 1 1 - 238
Environmental 19 - - - 23 - 2 - 44
Cuba 211 Clinical 141 - - - - - 1 - 142
Environmental 68 - - - - - - - 68
Veterinary - - - - 1 - - - 1
Venezuela 101 Clinical 76 6 1 - 5 10 3 - 101
Peru 37 Clinical 25 9 - 2 1 - - - 37
Ecuador 27 Clinical 27 - - - - - - - 27
Chile 19 Clinical 4 3 3 5 - - - - 15
Environmental 4 - - - - - - - 4
Guatemala 15 Clinical 14 - - - - - 1 - 15
Honduras 1 Clinical - - - - 1 - - - 1
Paraguay 1 Clinical - - - - - - 1 - 1
Uruguay 1 Environmental - - - - - 1 - - 1
Total
Clinical 1,717 107 25 22 50 339 90 9 2,359
3,486 Environmental 639 9 1 23 33 322 83 11 1,121
Veterinary - - - - 1 5 - - 6
Molecular data have been combined from studies reported in Argentina (Meyer et al. 2003, Refojo et al. 2009, Cattana et al. 
2013, Mazza et al. 2013, Cattana et al. 2014, Cattana et al. 2015, Cicora et al. 2015, Arechavala et al. 2017), Brazil (Casali et al. 
2003, Trilles et al. 2003, Igreja et al. 2004, Abegg et al. 2006, Ribeiro et al. 2006, Matsumoto et al. 2007, Lugarini et al. 2008, 
Ribeiro & Ngamskulrungroj 2008, dos Santos et al. 2008, Trilles et al. 2008, Costa et al. 2009, Andrade-Silva et al. 2010, Pinto 
Jr et al. 2010, Souza et al. 2010, Ferreira-Paim et al. 2011, da Silva et al. 2012, Freire et al. 2012, Silva et al. 2012, Cardoso et al. 
2013, Tsujisaki et al. 2013, Anzai et al. 2014, Nascimento et al. 2014, Brito-Santos et al. 2015, Headley et al. 2015, Castro e Silva 
et al. 2016, Figueiredo et al. 2016, Lomes et al. 2016, Souto et al. 2016, Aguiar et al. 2017, da Silva et al. 2017), Chile (Calvo et al. 
2001, Meyer et al. 2003, Solar et al. 2015), Colombia (Meyer et al. 2003, Escandón et al. 2006, Escandón et al. 2010, Firacative 
et al. 2011, Lizarazo et al. 2012, Lizarazo et al. 2014a, Lizarazo et al. 2014b, Noguera et al. 2015, Cogliati et al. 2016, Firacative et 
al. 2016, Noguera et al. 2017, Vélez and Escandón 2017), Cuba (Illnait-Zaragozi et al. 2010a, Illnait-Zaragozi et al. 2010b, Illnait-
Zaragozi et al. 2011b, Illnait-Zaragozi et al. 2013), Ecuador (Sánches et al. 2017), Guatemala (Meyer et al. 2003), Honduras 
(Boekhout et al. 2001), Mexico (Meyer et al. 2003, Olivares et al. 2009, Firacative et al. 2016, González et al. 2016), Paraguay 
(Firacative et al. 2016), Peru (Meyer et al. 2003, Bejar et al. 2015), Uruguay (Engelthaler et al. 2014) and Venezuela (Calvo et al. 
2001, Meyer et al. 2003, Firacative et al. 2016, Ferrara et al. 2017). *From Bolivia, Costa Rica, Dominican Republic, El Salvador, 
Haiti, Nicaragua, and Panama there is not data reported about the molecular type of cryptococcal strains.
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VNII/VNIV and two isolates VNI/VGII from Brazil, and 
five isolates VNI/VNII and one isolate VNI/VGII from 
Colombia (Aminnejad et al. 2012, Aminnejad et al. 2016).
When the mating type of the isolates was identified 
by specific PCR, the mating alpha was the most com-
mon in both C. neoformans and C. gattii isolates recov-
ered in Latin America, as noted globally (Kwon-Chung 
et al. 2014). However, in Colombia all C. gattii VGIII 
isolates recovered from Corymbia ficifolia detritus, and 
one VGI isolate recovered from Ficus spp. were mating 
type a (Escandón et al. 2010, Firacative et al. 2011), as 
well as 13 clinical and three environmental VGII isolates 
from Brazil (Brito-Santos et al. 2015, Souto et al. 2016), 
and two VGIII clinical isolates recovered in Mexico (Fi-
racative et al. 2016). Interestingly, there are no reports on 
C. neoformans mating type a in the region.
The use of MLST and WGS to further advance the 
understanding of C. neoformans and C. gattii popula-
tions has also been achieved in Latin America. Firstly, 
a highly clonal population structure of clinical and en-
vironmental isolates of C. neoformans var. grubii was 
revealed in Brazil (Ferreira-Paim et al. 2017), which is 
in agreement with the clonal evolution and dispersion of 
C. neoformans that has been reported worldwide, these 
results detail the absence or restriction of genetic re-
combination, and the persistence of widespread clones. 
Opposing this, the genetic population structure of many 
isolates of the less common C. neoformans var. neofor-
mans, from different geographical origin, including Co-
lombia, and from different sources, showed that this is a 
highly recombinant population, with the isolates being 
strictly correlated to each other, and characterised by 
high variability (Cogliati et al. 2016).
The global diversity of a number of C. gattii VGII 
isolates was also studied, which provided evidence on 
the evolution of this pathogen in North America and 
gave support to the extensive evolution in, and dispersal 
from, South America, most likely from the Amazonia 
and the Northeastern regions of Brazil, where C. gattii 
VGII strains have shown to have the most genetic vari-
ability, compared to isolates from the rest of the world 
(Engelthaler et al. 2014, Souto et al. 2016).
Additionally, Mexico and Colombia have been 
proposed to be the likely origins of the VGIII C. gat-
tii population, as isolates from these countries are the 
basal group of isolates recovered worldwide; they are 
very variable genetically, and have both mating types, 
which may lead to sexual reproduction and recombina-
tion events (Firacative et al. 2016).
Other molecular techniques employed in Latin 
American countries have allowed the identification 
and characterisation of cryptococcal isolates, although 
without determining the major molecular types. PCR 
fingerprinting with GACA4 primers was used for the ge-
notyping of the first environmental isolate of C. gattii 
recovered in Argentina (Meyer and Mitchell 1995, Davel 
et al. 2003). Electrophoretic karyotyping of 40 C. neo-
formans, and 11 C. gattii clinical isolates from Brazil, 
Chile and Venezuela showed a broad genotypic diversity 
among the isolates (Calvo et al. 2001). Sequencing of the 
internal transcribed spacer (ITS) identified one C. gattii 
isolate recovered from an immunocompetent patient in 
Chile (Solar et al. 2015), and one and five C. neoformans 
environmental isolates recovered from an almond tree in 
Cuba (Illnait-Zaragozi et al. 2012), and derived from pi-
geon excreta in Mexico (Canónico-González et al. 2013), 
respectively. In addition, ITS sequencing allowed for the 
discrimination of an uncommon species causing crypto-
coccosis, C. liquefaciens, in a HIV positive patient from 
Guatemala (Conde-Pereira et al. 2015). Lastly, using 
comparative genome hybridisation, the genome content 
of a clinical C. neoformans VNI strain from Argentina 
was examined, which showed that this strain shared 
most, if not all, of its genome with H99, the reference 
strain of C. neoformans var. grubii (Hu et al. 2008).
Diagnostic and identification of cryptococcal spe-
cies from clinical and environmental samples has also 
been possible by using molecular methodologies, some 
of which have been developed in Latin America. PCR of 
the capsular gene CAP59, followed by RFLP was used 
in Argentina to determine the serotypes of cryptococ-
cal strains directly from a yeast suspension, thus avoid-
ing DNA extraction and making serotype identification 
quick, simple and inexpensive (Siachoque et al. 2010). In 
Colombia, a nested PCR targeting the ITS region was de-
veloped for the diagnosis of C. neoformans and C. gattii 
from human samples, including bronchoalveolar lavage 
(BAL), bronchial lavage (BL), biopsy, and, cerebrospi-
nal fluid (CSF), showing a sensitivity and specificity of 
Fig. 1: distribution of Cryptococcus neoformans and C. gattii identified 
at molecular type level (n = 3486), recovered from clinical, environmen-
tala or veterinary sources in Latin America. Molecular data have been 
combined from studies reported in Argentina, Brazil, Chile, Colombia, 
Cuba, Ecuador, Guatemala, Honduras, Mexico, Paraguay, Peru, Uru-
guay, and Venezuela (Table III). Data from Bolivia, Costa Rica, Do-
minican Republic, El Salvador, Haiti, Nicaragua, and Panama about the 
molecular typing of cryptococcal strains has not been reported. a: C. 
neoformans has been mostly recovered from avian droppings, decaying 
organic matter, and soil (Casali et al. 2003, Ribeiro et al. 2006, Luga-
rini et al. 2008, Ribeiro and Ngamskulrungroj 2008, Andrade-Silva et 
al. 2010, Illnait-Zaragozi et al. 2010a, Souza et al. 2010, Ferreira-Paim 
et al. 2011, Canónico-González et al. 2013, Castro e Silva et al. 2016). 
C. gattii is associated with several tree species (Escandón et al. 2006, 
Trilles et al. 2008, Costa et al. 2009, Refojo et al. 2009, Escandón et al. 
2010, Firacative et al. 2011, Mazza et al. 2013, Anzai et al. 2014, Cattana 
et al. 2014, Brito-Santos et al. 2015, Vélez and Escandón 2017).
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100% (Rivera et al. 2015). In addition, in Colombia, two 
techniques to extract cryptococcal DNA from contami-
nated soil were standardised, namely glass beads with 
agarose blocks and an ultra-clean DNA soil kit (MoBio, 
Solano Beach, CA, USA), which allowed a faster yet spe-
cific detection of cryptococcal isolates from soil samples 
through the amplification of species-specific DNA using 
the primers CN4 and CN5 (Castañeda et al. 2004). The 
rapid, sensitive and specific identification of the eight 
major molecular types, including hybrid strains, from 
culture and directly from clinical samples is also now 
possible after the development of a hyperbranched rolling 
circle amplification of the phospholipase gene PLB1 in 
combination with a semi-nested PCR (Trilles et al. 2014).
Thus, the use of molecular techniques for the study 
of the etiological agents of cryptococcosis in Latin 
America, as elsewhere, shows an undoubted value espe-
cially for rapid detection and genetic epidemiology stud-
ies, and at the same time shows that these methodologies 
are complementary to traditional techniques.
Host-Cryptococcus - The role of C. neoformans and 
C. gattii as the major causative agents of fungal meningo-
encephalitis in humans and animals worldwide (Rajasing-
ham et al. 2017) has stimulated more than half-century’s 
Fig. 2: geographic distribution of Cryptococcus neoformans and C. gattii isolates from Latin America, identified at the molecular type level (n = 
3486). Molecular data have been combined from studies reported in Argentina, Brazil, Chile, Colombia, Cuba, Ecuador, Guatemala, Honduras, 
Mexico, Paraguay, Peru, Uruguay, and Venezuela (Table III). Data from Bolivia, Costa Rica, Dominican Republic, El Salvador, Haiti, Nicara-
gua, and Panama regarding the molecular typing of cryptococcal strains have not been reported.
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worth of investigations on these fascinating and versatile 
fungi. Nevertheless, many questions about this species and 
the interactions with the host are not yet fully elucidated, 
including: (1) whether reactivation of long-term latent in-
fection is a more important cause of cryptococcosis in pa-
tients than de novo acquisition from the environment; (2) 
the bases of the preference of some genotypes for certain 
hosts (i.e. immunosuppressed vs. immunocompetent) and 
target organs (i.e. brain vs. lung); (3) the mechanism by 
which the infection becomes persistent and/or recurrent 
despite that in vitro resistance to antifungal drugs does 
not seem to be a problem for cryptococcal treatment; and 
(4) the diverse pathways related to sexual reproduction, 
among many others (Rodrígues et al. 2007).
In Latin American, specifically in Argentina, Bra-
zil and Cuba, different investigations related with these 
topics have been conducted mostly in order to reveal and 
comprehend host-pathogen interactions, to investigate the 
role of interactions between the yeasts and other microor-
ganisms, and to review alternative approaches to antifun-
gal treatments against cryptococcosis and other mycosis. 
A clear majority of the authors have attempted then to un-
derstand the role of the immune cells and the cytokines/
antibodies induction not only from human clinical sam-
ples but also by using in vitro and in vivo models.
In AIDS patients with cryptococcal meningitis, cyto-
kine patterns in the CSF and sera were shown to be relat-
ed to fungal burden and clinical outcome. CSF levels of 
IL-8, IL-12p40, IL-17A, TNF-α, INF-γ and sera TNF-α 
were significantly higher among survivors, which indi-
cates that this progressive shift in cytokine expression 
favouring a Th1 pattern is crucial in controlling cryp-
tococcal infection and would be a prognostic marker in 
cryptococcal meningitis (Mora et al. 2015, Mora et al. 
2017). In addition, the study of the cytokine profile of 
human peripheral blood mononuclear cells (PBMCs) of 
healthy individuals, after in vitro stimulation with heat-
killed C. gattii and C. neoformans (40 different strains), 
demonstrated that clinical heat-killed C. gattii isolates 
induced a more pronounced inflammatory response with 
higher concentrations of pro-inflammatory cytokines 
(IL-1β, TNF-α and IL-6 and the Th17/22 cytokine IL-17 
and IL-22) compared to other Cryptococcus species and 
non-clinical C. gattii, which is dependent on TLR4 and 
TLR9 as cellular receptors (Schoffelen et al. 2013).
By using vertebrate models, Garro et al. (2011a), 
Garro et al. (2011b) showed that in rats, peritoneal eo-
sinophils can migrate into lymphoid organs to act as an-
tigen-presenting cells of C. neoformans (strain 102/85) 
antigens, priming naïve and re-stimulating infected 
animals to induce T-cell and B-cell responses, and the 
development of a Th1 microenvironment with increased 
levels of nitric oxide (NO) synthesis and C. neoformans-
specific immunoglobulin production, which all lead to a 
protective immune response against subsequent infec-
tion with fungus. Also in rats, the mechanisms involved 
in macrophage apoptosis promoted by cryptococcal 
glucuronoxylomannan (GXM) through NO generation 
showed to be novel immunomodulatory mechanisms 
that could contribute to limit inflammation during infec-
tion in these group of rodents (Chiapello 2017). Obtained 
from mice, the monoclonal antibodies (mAb) 4B3 were 
shown to stimulate phagocytosis of the C. neoformans 
(strain 028 LMIPK) by macrophages without fungicidal 
effect, thus favouring yeast dissemination and decreas-
ing the survival of mice due to cryptococcal infection 
(Gato-Armas et al. 2006, Illnait-Zaragozi et al. 2011a).
In addition to cryptococcosis alone, mouse models 
have been also used to study the influence of or interac-
tion between other fungi, bacterial and viral agents, and 
C. neoformans and C. gattii infections. Fungal-fungal 
specific interactions between C. neoformans and H. 
capsulatum, which co-exist in the environment, that can 
impact in virulence and disease were investigated. Co-
infected mice showed to have significantly higher mor-
tality than infection with C. neoformans (strain H99) or 
H. capsulatum alone, or acapsulated strains, as shown by 
higher pulmonary fungal burden in co-infected animals. 
Enhanced pellicle formation with a hybrid polysaccha-
ride matrix with higher reactivity to GXM mAbs and 
increased resistance to phagocytosis and killing by mac-
rophages was also observed, which together indicate that 
a microbial interaction involving the transfer of viru-
lence traits may translate into enhanced lethality during 
mixed fungal infections (Cordero et al. 2016). Secondly, 
the influence of microbiota in the host response against 
C. gattii (strain L27/01) was demonstrated. Germ-free 
(GF) mice were more susceptible to infection, showing 
lower survival, higher fungal burden in the lungs and 
brain, increased behavioural changes, reduced levels of 
inflammatory cytokines (IFN-γ, IL-1β and IL-17), and 
lower NFκBp65 phosphorylation compared to conven-
tional mice, which were associated with smaller yeast 
cells and polysaccharide capsules in the lungs, and less 
tissue damage. Moreover, macrophages from GF mice 
showed reduced ability to engulf, produce reactive oxy-
gen species (ROS), and kill C. gattii. Restoration of mi-
crobiota in mice that received feces from conventional 
animals or administration with Escherichia coli, made 
mice more responsive to infection, which was associated 
with increased survival and higher levels of inflamma-
tory mediators (Costa et al. 2016). More recently, the in-
teraction between C. gattii infection (strain L27/01) and 
the concurrent infection with influenza A virus (IAV) 
strain H1N1 was studied. This co-infection resulted in 
a major increase in morbidity and mortality, with severe 
lung damage and a high brain fungal burden when mice 
were infected in the acute phase of influenza multipli-
cation, indicating that IAV infection is a predisposing 
factor for severe disease and adverse outcomes in mice 
co-infected with C. gattii. IAV not only alters the host 
response to the yeast, leading to recruitment of signifi-
cantly more neutrophils and macrophages into the lungs, 
but also induces the production of type 1 interferons 
(IFN-α4/β) and significantly reduces the levels of IFN-γ, 
which is associated with an impaired immune response. 
Reduced phagocytosis, killing of cryptococci and pro-
duction of ROS by IAV-infected macrophages were also 
shown, leading to increased proliferation of the fungus 
within macrophages (Oliveira et al. 2017).
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In vitro, the interaction between antibodies and the 
cryptococcal capsule, and the effect of protective and 
non-protective mAbs on C. neoformans H99 replication 
and the capsule’s physical properties have been also ex-
amined. Protective mAbs were shown to directly alter 
cell division by trapping and preventing the full release 
of newly budded cells. This effect is caused by an Ab-
mediated increase in capsule stiffness, involving cross-
linking of GXM molecules. The ability of mAbs to 
impair C. neoformans budding through changes in the 
capsule’s mechanical properties indicates a new, non-
classical mechanism of Ab function, and presents im-
portant implications for understanding Ab-mediated im-
munity (Cordero et al. 2013). As the interaction between 
C. neoformans H99 and the amoebae is similar to that 
of the yeast-macrophage association, the participation of 
fungal virulence-associated structures with Acantham-
oeba castellanii was evaluated by Rizzo et al. (2017). 
Fungal extracellular vesicles (EVs) and the GXM were 
shown to be internalised by A. castellanii with no impact 
on the viability of amoebal cells. However, EVs, but not 
free GXM, modulate antifungal properties of A. castel-
lanii by inducing enhanced yeast survival. Phagocytosis 
of C. neoformans by amoebal cells and the pathogenic 
potential in a Galleria mellonella model are not affected 
by EVs, but previous interactions with A. castellanii ren-
dered fungal cells more efficient in killing this inverte-
brate host, which all support the notion that interaction 
of C. neoformans with environmental predators results 
in enhanced virulence (Rizzo et al. 2017).
Both in vivo and in vitro, the role of mammalian 
β-galactoside-binding protein Galectin-3 (Gal-3) in C. 
neoformans H99 infection was also revealed. Gal-3 lev-
els no only augments in human sera but also in spleen, 
lung, and brain tissues of infected mice. Gal-3-deficient 
mice are more susceptible to cryptococcosis than wild-
type animals, as the first group present higher fungal 
burden and lower animal survival. In vitro experiments 
showed that Gal-3 also inhibits fungal growth and exerts 
a direct lytic effect on C. neoformans EVs, which could 
benefit the host (Almeida et al. 2017).
Regarding the research efforts targeting alternative 
antifungal strategies, Baronetti et al. (2006), Baronetti 
et al. (2011) showed that subcutaneous pretreatment of 
rats with heat killed cells of the C. neoformans strain 
102/85 (HKC) emulsified in complete Freund adjuvant 
(CFA), promoted protection against an intraperitoneal 
challenge with viable C. neoformans var. grubii with 
significantly better clearance of yeasts from tissues, a 
lower concentration of GXM in serum and tissues, and 
better histopathological parameters compared to un-pre-
treated infected rats. Passive immunisation with a mAb 
to glucosylceramides (GlcCer), a lipid that is present at 
the fungal plasma membrane, cell wall, and secretory 
vesicles, and which induces antifungal antibodies and 
regulates the virulence of C. neoformans in animal in-
fections, significantly reduced host inflammation and 
prolonged the survival of mice lethally infected with 
C. neoformans strain 24067 (Serotype D), revealing a 
potential therapeutic strategy to control cryptococco-
sis (Rodrigues et al. 2007). In vitro, mAb-based drugs 
have shown to be potentially a powerful alternative to 
standard antifungals, and although C. neoformans H99 
was reported to be the least susceptible among other 
fungal species, it was found that wheat germ agglutinin 
(WGA), linked to the effector Fc region of murine IgG2a 
(WGA-Fc), was able to inhibit in vitro fungal growth, to 
increase phagocytosis by macrophages, as well as their 
antifungal functions (Liedke et al. 2017). Lastly, treat-
ment of C. neoformans H99 cells with WGA followed 
by infection of mice also delayed mortality relative to 
animals infected with untreated fungal cells. Reduced 
brain colonisation by lectin-treated cryptococci was also 
observed. Blocking chitin-like oligomers also rendered 
yeast cells less efficient in their ability to associate with 
phagocytes. WGA did not affect fungal viability, but in-
hibited GXM release to the extracellular space and cap-
sule formation. In WGA-treated yeast cells, genes that 
are involved in capsule formation and GXM traffic had 
their transcription levels decreased in comparison with 
untreated cells (Fonseca et al. 2013).
In this way, the wide variety of approaches and meth-
odologies used in different laboratories from Argentina, 
Brazil and Cuba have globally contributed to understand 
particular issues related to the host-pathogen interac-
tions in cryptococcosis.
Laboratory data: Antimicrobial susceptibility of 
clinical and environmental isolates - Most of the data in 
this topic have been generated on the numerous studies 
carried out in Brazil and Argentina. The studies have 
been focused on the methodology and interpretation of 
the phenotypic tests employed, the susceptibility data 
generated with clinical and environmental isolates and 
the study of resistance to some antifungals (Table IV).
Methodology and interpretation of results - Two ref-
erence methods have been used in Latin American stud-
ies to determine the minimal inhibitory concentration 
(MIC), the Clinical Laboratory Standard Institute (CLSI) 
microdilution method from M27-A3, and the EDef 7.2 
from the European Committee on Antimicrobial Suscep-
tibility Testing (EUCAST). Several additional techniques 
have been developed to simplify the standard ones, such 
as, time kill curves (TKC), E-Test strips, and a disk dif-
fusion method (Ochiuzzi et al. 2010, Córdoba et al. 2015, 
de Oliveira et al. 2017). Recently, the use of flow cytom-
etry (FC) was evaluated in two publications, which both 
showed a positive significant correlation (Benaducci et al. 
2015, Morales et al. 2015). In one of them, the conclusion 
was that FC has an excellent correlation with the standard 
methods, and it is a reliable, fast, and safe method to test 
the susceptibility to AmB (Benaducci et al. 2015). In the 
other study, the antifungal susceptibility of 17 clinical 
isolates of C. neoformans and 18 C. gattii VGII, was ana-
lysed by both the microdilution method (CLSI M27-A3) 
and FC, showing that FC allowed to determine MIC for 
AmB in a 2 h incubation time, with MICs data obtained 
on the same day (Morales et al. 2015).
In three additional studies, the epidemiological cut-
off values (ECV) for AmB, 5FC, FCZ, itraconazole 
(ITZ), posaconazole (PCZ) and voriconazole (VCZ), 
were established (Espinel-Ingroff et al. 2012a, Espinel-
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Ingroff et al. 2012b, Córdoba et al. 2016) and recently, a 
review done by the Venezuelan group was reported (Fer-
rara et al. 2017). The first two studies were conducted as 
a part of a collaborative international effort with the par-
ticipation of Argentina, Brazil, Cuba, and Mexico (Es-
pinel-Ingroff et al. 2012a, Espinel-Ingroff et al. 2012b). 
The rationale of this work was to propose clinical break-
points for C. neoformans and C. gattii, according to the 
molecular types, which was not available, as such EVCs 
for AmB and 5FC, on basis of MICs (CLSI methodol-
ogy) were determined. ECVs are commonly used to 
separate wild-type (WT) isolates from isolates with re-
duced susceptibility to antifungal drugs with probable 
acquired resistance mechanisms, are useful to monitor 
the emergence of strains with mutations that could lead 
to reduced antifungal susceptibility to antifungal drugs, 
however they should not be used as predictor of clini-
cal outcome. In the study by Córdoba et al. (2016) with 
Argentinian isolates, the highest ECVs, which included 
≥95% of the WT population studied, was observed for 
5FC and FCZ (32 µg/mL each), values that were higher 
than those previously proposed by Espinel-Ingroff et al. 
(2012a), Espinel-Ingroff et al. (2012b).
Clinical and environmental data - The studies are 
presented in Table IV and the data is variable; hence, 
it is important to analyse each one of the articles’ data, 
separately (Arechavala et al. 2009, Illnait-Zaragozí et al. 
2009, Matos et al. 2012, Silva et al. 2012, Andrade-Silva 
et al. 2013, Teodoro et al. 2013, Figueiredo et al. 2016, 
Herkert et al. 2016, Reichert-Lima et al. 2016, Nasci-
mento et al. 2017).
As a general observation, clinical C. gattii strains 
are more resistant to FCZ in comparison to clinical C. 
neoformans strains. Otherwise, for AmB and 5FC no 
difference has been reported. Another general observa-
tion is that environmental isolates are more susceptible 
to antifungal drugs than clinical isolates.
It is important to mention the work by de Oliveira 
et al. (2017) describing the phenomenon of tolerance to 
AmB in some low-MIC strains of C. neoformans and C. 
gattii. Clinical studies are warranted to ascertain the rel-
evance of this occurrence as a tool for guide treatment. 
Additionally, resistance to FCZ was studied by Bosco-
Borgeat et al. (2016), in which they found that lanosterol 
14-α-demethylase was involved in FCZ resistance in C. 
neoformans clinical isolates. The sequencing revealed 
the G1855A mutation in three isolates, resulting in the 
enzyme amino acid substitution G484S. These strains 
were isolated from two fluconazole-treated patients. Im-
portantly, this mutation would not intervene in the sus-
ceptibility to the other widely use azoles, ITZ and VCZ.
Novel compounds for treatment - The synthesis of 
novel compounds has been explored by one research 
group in Colombia (Acosta et al. 2015, Ramírez et al. 
2015, Montoya et al. 2016, Ramírez-Prada et al. 2017) and 
by two Brazilian groups (da Silva et al. 2016, Palanco et al. 
2017) and their preliminary results look promising. Pyr-
azolonaphthyridines (Acosta et al. 2015), thiazole-based 
pyrimido[4,5-b] [1,4] diazepines (Ramírez et al. 2015), 
chalcones and N-aryl-2-pyrazolines (Montoya et al. 
2016), and quinolone-based pyrazoles (Ramírez-Prada et 
al. 2017) have shown antifungal activity not only against 
C. neoformans but also against Candida albicans, with 
some of them showing fungicidal, rather than fungistatic 
activity, which makes them good antifungal candidates.
Laboratory data: Early diagnosis in HIV patients - 
Early diagnosis of cryptococcosis in HIV infected pa-
tients has been a topic of interest in Latin America since 
1995 (Negroni et al. 1995, Lizarazo et al. 2002, Costa 
et al. 2013). In all, diagnosis was established with the 
determination of circulating antigen (CrAg) with the La-
tex test. Results of the studies were dissimilar but the 
importance of the CD4+ cells count to increase the sen-
sitivity of the test was established. In 2011, a new CrAg 
lateral flow assay (CrAg LFA) was developed and pre-
liminary experience in Colombia, Brazil, and Argen-
tina (Escandón et al. 2013, Vidal et al. 2016, Frola et al. 
2017) showed comparable results to that demonstrated 
globally (Huang et al. 2015, Wake et al. 2018). That is, 
a Point-of-Care Test (POCT) like CrAg LFA plays an 
important role in the early diagnosis of cryptococcosis 
in HIV patients, especially in resource limited settings. 
Inclusion of the CrAgLFA in the National Guides for 
managements of the patients with AIDS must be a com-
promise of the countries in the region without delay.
Searching the environmental niche: From avian 
droppings to tree hollows - The saprobic nature of the 
Cryptococcus spp. is a well-established fact. Infection 
with Cryptococcus spp. is invariably acquired by ex-
posure to blastoconidia or basidiospores from an exog-
enous source and the host becomes an accident in the life 
cycle of the yeast. Consequently, studies on the natural 
reservoir of C. neoformans and C. gattii hold paramount 
interest even though they require a very extensive, pro-
grammed, coordinated and sequential field-work. In 
some Latin-American countries, this search has been 
conducted for many years. For this review, we will focus 
on the most recent studies (Table V).
The search for the habitat of these yeasts have been 
successfully achieved in many parts of the world, includ-
ing Latin America, following Emmons’ findings (Em-
mons 1960) on the strong association of cryptococci with 
soil enriched with dry pigeon excreta. Following this, 
studies on the recovery of the yeasts, not only from pi-
geon droppings but also from other bird faeces, especially 
from captive birds, have been successful good in Latin 
America (Álvarez et al. 2010, González-Hein et al. 2010, 
Ferreira-Paim et al. 2011, Andrade-Silva et al. 2012, Taka-
hara et al. 2013, Teodoro et al. 2013). Although most of the 
isolates therein recovered were identified as C. neofor-
mans, VNI, mating type alpha, it is worth mentioning that 
in one study (Teodoro et al. 2013) C. gattii was recovered 
in 5.2% of samples. Globally, it is known that most of the 
isolates recovered from bird droppings are C. neoformans 
(Kwon-Chung et al. 2014), with the percentage of recov-
ery varying from place to place from 2% up to 70%.
From the numerous studies done globally on the 
search for the fungus in avian droppings, it has been 
very well established that bird droppings shielded from 
direct sun and ultraviolet light are an excellent substrate 
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for the growth of the yeasts because of their high urea 
concentrations that is converted to ammonium, and car-
bamate by the urease enzyme, which is one of the land-
mark enzymes of the genus.
On the other hand, by the end of the 80s, the natural 
habitat of C. gattii was still unknown, until 1990, when 
David Ellis and Tania Pfeiffer (Ellis and Pfeiffer 1990) 
published their seminal paper revealing that the habitat 
of C. gattii in Australia was related to Eucalyptus ca-
maldulensis trees.
Following the Australian report, recovery of C. gattii 
from E. camaldulensis detritus was achieved initially in 
Mexico (Licea et al. 1999) and later in other Latin Ameri-
can countries. However, it is of utmost importance that 
the work done by Marcia Lazera and her group in Fio-
cruz, Rio de Janeiro, Brazil, as they demonstrated that 
the niche of C. gattii is not only related with Eucalyptus 
spp. but with an uncountable number of tree species, with 
isolates recovered especially from tree hollows and de-
cayed woods (Lazera et al. 1998, Fortes et al. 2001). Im-
portantly, their studies revealed as well that trees are also 
a habitat for C. neoformans (Lazera et al. 1996), and that 
sometimes both species are found in the same tree. Those 
findings encouraged a group in Colombia to search for 
the habitat of C. gattii in a variety of trees and, described, 
for the first-time, almond trees (Terminalia catappa) as 
the natural habitat of C. gattii, serotype C, VGIII (Calle-
jas et al. 1998). Recently the serotype and molecular type 
of this species has been isolated form Tipuana tipu a na-
tive tree from Argentina (Mazza et al. 2013).
Following Lazera’s findings, tree hollows, decayed 
wood and soil samples have been described as the habitat 
of C. gattii, and C. neoformans in a plethora of indig-
enous and imported trees in some Latin-American coun-
tries, including: Argentina (Refojo et al. 2009, Mazza et 
al. 2013, Cattana et al. 2014), Brazil (Costa et al. 2009, 
Andrade-Silva et al. 2012, Anzai et al. 2014, Brito-Santos 
et al. 2015, Castro e Silva et al. 2016), Chile (Toro-Zúñi-
ga et al. 2015), Colombia (Escandón et al. 2005, Escan-
dón et al. 2010, Firacative et al. 2011, Mak et al. 2015, 
Noguera et al. 2015, Vélez and Escandón 2017), and Cuba 
(Illnait-Zaragozí et al. 2010a, Illnait-Zaragozí et al. 2012) 
(Table V). Some of the trees genus and species that are 
the reservoir of C. gattii as well as C. neoformans are: 
E. camaldulensis, E. tereticornis, Eucalyptus spp., Aca-
cia spp., Corymbia ficifolia, Phoenix spp., Tipuana tipui, 
Moquilea tomentosa, Cassia grandis, Ficus spp., Croton 
spp., Cedrus spp., T. catappa and Tabebuia rosea.
The rationale for the association of C. neoformans 
and C. gattii with decayed wood as a primary ecological 
niche for both species is that they are lignicolous, the 
so-called wood decay fungi, due to laccase (diphenoloxi-
dase), an enzyme that oxidizes diphenolic substrates to 
form long polymers of melanin. Laccase provides pro-
tection to the fungus in the environment, and it is one of 
the most important and most studied virulence factors in 
Cryptococcus (Kwon-Chung et al. 2014).
Environmental isolates have been analysed with some 
phenotypic and molecular techniques. Antifungal suscep-
tibility has been determined in some of them (Andrade-
Silva et al. 2013, Teodoro et al. 2013, Firacative et al. 
2016) and the results are quite variable. Andrade-Silva 
et al. (2013) reported that 6.2% of the environmental C. 
neoformans isolates were resistant to FCZ. Although in 
general, clinical isolates have lower susceptibility than en-
vironmental isolates to AmB and ITZ and environmental 
isolates have had lower susceptibility than clinical isolates 
to FCZ, VCZ, and KCZ, Teodoro et al. (2013) reported 
that all environmental C. neoformans isolates were sus-
ceptible to the antifungals tested. In addition, Firacative 
et al. (2016) reported that C. gattii VGIII environmental 
isolates were less susceptible to 5FC, PCZ, VCZ, ITZ and 
FCZ, and more susceptible to AmB, compared with clini-
cal and veterinary isolates. Clinical isolates of C. neofor-
mans were reported to be less susceptible to antifungal 
drugs than environmental isolates (Souza et al. 2010). 
Although the contribution of these studies is of great im-
portance, more work needs to be done to have enough 
data for an analysis, especially for the correlation between 
the source of the isolates, clinical and environmental, and 
their antifungal susceptibility profiles.
As it was mentioned earlier, molecular studies have 
been done with some of the environmental isolates, in-
dicated on Table III and Table V, and the importance of 
the studies done in Latin America was revealed when the 
global diversity of the C. gattii VGII isolates was stud-
ied, and the results provided evidence on the evolution of 
this pathogen in North American Pacific Northwest and 
the dispersal from South America, most likely from the 
Amazonia and the Northeast of Brazil, where C. gattii 
VGII strains have shown to be the most variable geneti-
cally (Engelthaler et al. 2014).
Many questions about the presence of the fungus in 
the environment were still without a complete answer, 
and one of them was related to the survival time of the 
blastoconidia in the samples. In this way, a couple of 
studies were carried out in Latin America, and the find-
ings indicated that blastoconidia could remain viable 
from 45 days up to ten years (Álvarez et al. 2013, Escan-
dón and Castañeda 2015). Efforts have been also made 
in the design of a culture medium, which use results ap-
propriate for environmental studies to recover the fun-
gus with a major efficiency from the environment (Silva 
et al. 2012, Álvarez et al. 2013). It is worth mentioning 
that the Staib culture medium supplemented with seeds 
of Guizotia abyssinica (niger seeds) is the medium of 
choice for environmental studies. These seeds provide 
the substrate for the laccase and the end product is mela-
nin, which is associated with the cell walls and gives the 
colonies a characteristic brown pigment allowing for the 
differentiation from other yeast colonies.
Related to C. gattii, the pioneer environmental stud-
ies that have been done in Latin America and the ongo-
ing ones with the assistance of molecular tools will allow 
to understand more clearly the expansion of the ecologi-
cal niche of this species.
Particularly in Colombia, a study on ecological niche 
modelling was also used to forecast the distribution of 
cryptococcal species and to produce risk area maps for 
cryptococcal disease in the country (Mak et al. 2015). 
This study was conducted following the success of accu-
rately identifying ecological niche areas of human and an-
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imal cases of C. gattii in British Columbia, Canada (Mak 
et al. 2010) and also complements the report on niche 
prediction of C. neoformans and C. gattii in Europe (Co-
gliati et al. 2017). As ecological niche modelling is a great 
tool to very likely predict where these pathogenic yeasts 
survive in the environment and therefore to identify areas 
with high risk of infection, it would be relevant to conduct 
such studies in all Latin-American countries, in order to 
increase awareness of this disease in regions at risk of en-
vironmental colonisation of C. neoformans and C. gattii.
Concluding remarks - The study of cryptococcosis 
and its etiological agents have been taking place in several 
Latin-American countries for several years and because of 
this, significant progress has been made on topics such as 
clinical epidemiology, laboratory identification and typing 
of cryptococcal strains, searching, and understanding the 
environmental niche, and recently, on the basic biology and 
population genetics of C. neoformans and C. gattii.
Key points - (i) globally, C. neoformans molecular 
type VNI, causes more than 90% of the cases of cryp-
tococcosis in Latin America and the main risk factor for 
acquiring it (70-90%) is to be infected with HIV. C. gattii, 
VGII and VGIII, are also recovered, affecting otherwise 
healthy individuals; (ii) AmB and FCZ are the antifungal 
drugs of choice, since 5FC is unavailable in the region; (iii) 
laboratory diagnoses and species or molecular type iden-
tification are performed with the standardised protocols; 
(iv) determination of the antifungal susceptibility shows 
that in 90% of cases, both species are susceptible to the 
antifungals tested, namely: AmB, 5FC, FCZ, PCZ, VCZ, 
and ITZ. Particularly, C. gattii VGIII, serotype C isolates 
have shown decreased susceptibility to azoles, especially 
to FCZ; (v) molecular studies of clinical and environmen-
tal isolates show that in Latin America, C. neoformans, 
molecular type VNI, is not only predominant among the 
clinical cases, but also in the environment, followed by 
C. gattii molecular type VGII, with similar proportions 
in both clinical-, and environmental sources; (vi) a great 
amount of information is from the Latin American studies 
on the environmental niche, especially for C. gattii; (vii) 
the increasing application of genotyping methods in Latin 
America, has also greatly contributed to the global study 
of C. neoformans and C. gattii, to the recognition of their 
great inter-, and intra-species genetic diversity, to under-
stand how these pathogenic yeasts have spread around the 
world and what is their population structure, and to better 
define some disease aspects of cryptococcosis, an impor-
tant mycosis in the region.
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